1612854-63-3

Basic information

• Product Name: C₆₆H₇₄N₈O₇
• Synonyms: C₆₆H₇₄N₈O₇
• CAS NO: 1612854-63-3
• Molecular Weight: 1091.36
• Mol File: 1612854-63-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₆₆H₇₄N₈O₇(CAS DataBase Reference)
• NIST Chemistry Reference: C₆₆H₇₄N₈O₇(1612854-63-3)
• EPA Substance Registry System: C₆₆H₇₄N₈O₇(1612854-63-3)

Safety Data

• Hazardous Substances Data: 1612854-63-3(Hazardous Substances Data)

Upstream product

• 1419387-01-1 C₁₃H₁₅IO 
• 1419386-99-4 C₁₄H₁₇IO 
• 1419386-97-2 C₁₄H₁₈O 
• 1419386-48-3 C₁₄H₁₆O₂ 
• 13336-31-7 4-methoxylindanone 
• 40731-98-4 4-hydroxy-2,3-dihydroindan-1-one 
• 119-84-6 C₆H₄(CH₂CH₂C(O)O) 
• 1612854-60-0 C₅₈H₆₀N₆O₅ 
• 1612854-59-7 C₂₈H₃₄BN₃O₅ 
• 1612854-58-6 C₂₂H₂₂BrN₃O₃ 
• 1612854-57-5 C₂₂H₂₄BrN₃O₄ 
• 1612854-56-4 C₃₇H₃₈F₃N₃O₅S 
• 1612854-55-3 C₂₉H₃₆BN₃O₄ 
• 1612854-54-2 C₂₃H₂₄BrN₃O₂ 

Relevant articles and documents

SPIRO RING COMPOUND AS HEPATITIS C VIRUS (HCV) INHIBITOR AND USES THEREOF FIELD OF THE INVENTION

A compound of formula (I) or a stereoisomer, a geometric isomer. a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof is provided, which can be used for treating HCV infection or a HCV disorder. Also a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof are provided, which can also be used for treating HCV infection or a HCV disorder.